Placeholder Banner

BIO and AUTM Submit Amicus Brief in Patent Venue Case, TC Heartland LLC v. Kraft Food Group Brands LLC (U.S. Supreme Court)

March 8, 2017

BIO and the Association of University Technology Managers (AUTM) submitted an amicus brief in TC Heartland, LLC v. Kraft Food Group Brands LLC at the Supreme Court of the United States.

BIO and AUTM have a strong interest in a balanced and fair patent enforcement system. BIO has a strong interest in ensuring its members can enforce their patents in convenient and logical forums – such as where they are engaged in efforts to commercialize their patented inventions.

At the same time, BIO and AUTM recognize manipulating patent venue in an abusive manner is not sound policy and is not necessary to protect the legitimate interests of patent holders.

There has been a significant concentration of patent-infringement suits in the Eastern District of Texas. BIO’s members are often defendants in patent suits, not just plaintiffs – and BIO does not believe it is good for the system if more than 40% of patent cases come up through a single district.

But attempting to resolve those issues through this case would do significantly more harm than good. This case presents the court with a binary choice limited to patent suits. BIO and AUTM say the court should either dismiss this case or should affirm, rather than legislating an obsolete approach to venue that Congress has not endorsed.

Related Resources
16-341 BIO TC Heartlend Amicus
BIO and AUTM Submit Brief of Amicus Curiae in TC Heartland LLC v. Kraft Food Group Brands LLC (Supreme Court of the United States)
Discover More
BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …
On February 10, 2025, BIO filed an amicus brief in the U.S. District Court for the District of Columbia, supporting the lawfulness of plaintiff Eli Lilly's proposed 340B rebate model. The 340B Drug Pricing Program ("340B"), through which Medicaid…
BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit urging rehearing of a case involving whether certain Teva Pharmaceuticals patents had been properly listed in FDA’s Orange Book (Approved Drug Products with Therapeutic…